论文部分内容阅读
恩西地尼 (enasidenib) 是由Celgene公司开发的首个异柠檬酸脱氢酶2抑制剂, 用于治疗携带异柠檬酸脱氢酶2基因突变的成人复发性或难治性急性髓性白血病, 于2017年8月1日被FDA批准上市.本文对其药效学、药动学、临床研究及不良反应等进行综述.“,”Enasidenib is a first-in-class isocitrate dehydrogenase-2 inhibitor approved by FDA on August1, 2017. It was developed by Celgene Corporation and indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Its pharmacodynamics, pharmacokinetics, clinical study and adverse reaction were reviewed in this paper.